Never before has there been so much pressure in the biotechnology industry to decrease development time! Our technology is embraced as a critical means to accelerate product development and achieve earlier regulatory approvals, speed to market and increased earnings.

Convergent Bioscience has become the Platinum Standard for characterizing proteins, peptides and other biologicals. We are the method of choice for charge based separations, due to our proprietary technology for whole column detection capillary isoelectric focusing (cIEF).

Our clients include emerging companies, as well as the largest pharmaceutical and biotechnology companies in the world, such as Abbott, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Centocor, Eli Lilly, Genentech, Genzyme, GSK, Merck, Novartis, PDL, Pfizer, Sanofi Aventis, Serono and Wyeth. Our iCE280 is used from Formulation to lot release in QC.

Please click on ‘Our Promise’ to review our commitment to you!